Current Health, an AI-powered wearable device for patient monitoring, has received class II clearance from the FDA for hospital care, the company recently announced.
Scotland-based Current uses its proprietary algorithms with the device to analyze data and relevant patient information to offer insights about a person’s health. Through continuous and automatic patient monitoring, the device allows physicians to take a proactive approach if a patient’s condition worsens after receiving treatment and potentially intervene earlier to reduce unnecessary hospital readmissions.
Current is in use with U.K. healthcare providers in a post-acute setting, including Dartford and Gravesham NHS Trust, according to the company.
In a recent study, the Dartford and Gravesham NHS Trust’s Hospital at Home team was able to reduce home visits 22 percent and hospital readmissions and emergency department visits after using the tool to remotely monitor patients who were recently released from the hospital.
Current Health is also currently being used to detect patient deterioration earlier and improve health outcomes at Mount Sinai Brooklyn, according to a release.
“The Mount Sinai Health System works with innovative and leading-edge companies like Current to support our commitment to providing world-class patient care. Current’s continuous and proactive monitoring platform has the potential to alert us to patient deterioration faster and give our team data insights they can act on earlier,” Scott Lorin, MD, president of Mount Sinai Brooklyn, said in a statement.
The clearance means the device has now been approved for use in both the United States and the European Union. The company plans to display Current Health during the HIMSS19 trade show in Orlando, Florida, next week.